NCT02738502 - Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 6, 2016

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2020

Conditions

Maternal-fetal Infection Transmission

Interventions

DRUG

darunavir monotherapy

darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.

Trial Locations (23)

31059

CHU Toulouse, Toulouse

33000

Groupe hospitalier Pellegrin, Bordeaux

33075

Hôpital Saint André, Bordeaux

35000

CHU Rennes Hôpital Pontchaillou, Rennes

44093

Hôtel Dieu, Nantes

66046

CHU de Perpignan, Perpignan

69307

Hôpital de la croix Rousse, Lyon

75010

Hôpital Lariboisiere, Paris

75012

Hôpital Armand Trousseau, Paris

75013

Hôpital la Pitié Salpétrière, Paris

75014

Groupe hospitalier Cochin-Broca- Hôtel Dieu, Paris

75015

HEGP, Paris

Hôpital Necker Enfant malades, Paris

75018

Hôpital Bichat - Claude Bernard, Paris

75020

Hôpital Tenon, Paris

91106

Hôpital Sud Francilien, Corbeil-Essonnes

92140

Hôpital Antoine Béclère, Clamart

92151

Hôpital Foch, Suresnes

92700

Hôpital Louis Mourier, Colombes

93140

Hôpital Jean Verdier, Bondy

94275

Hôpital Bicêtre, Le Kremlin-Bicêtre

95100

CH Victor Dupouy, Argenteuil

06202

CHU Archet 1, Nice

All Listed Sponsors

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV